BioSpecifics Technologies Corp. is a profitable biopharmaceutical company that has been involved in the development of an injectable collagenase clostridium histolyticum, or CCH, for multiple indications. Injectable collagenase is marketed in the U.S. for two indications, Dupuytren’s contracture and Peyronie’s disease, by BioSpecifics’ partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and also for Peyronie's disease in Europe. The XIAFLEX development pipeline includes several additional promising indications. Endo is managing development of cellulite, frozen shoulder, canine lipoma, lateral hip fat and plantar fibromatosis. BioSpecifics is managing the clinical development of human lipoma and plans to initiate clinical development of uterine fibroids in the second half of 2016.

View the BioSpecifics
2016 Corporate Presentation